Skip to navigation Skip to content



Further Data from Phase 2 Statins Trial in Progressive MS Show Effect on Cognition: Phase 3 Study Underway

June 9, 2017

New data have been published from a completed phase 2 study of the cholesterol-lowering drug simvastatin in people with secondary progressive MS, indicating improvements in some aspects of cognitive function after 2 years among those given simvastatin. Previously reported results suggested that simvastatin reduced the rate of brain atrophy, or shrinkage.  A large phase 3 trial of simvastatin is underway, with co-funding from the National MS Society and others, being led by Dr. Jeremy Chataway (University College London).

Read more on the website of University College London Hospitals

Read the scientific paper, and the accompanying editorial

Read more about the phase 3 statins trial


About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. There is currently no cure for MS. Symptoms vary from person to person and range from numbness and tingling, to mobility challenges, blindness and paralysis. An estimated 1 million people live with MS in the United States. Most people are diagnosed between the ages of 20 and 50, and it affects women three times more than men.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, funds cutting-edge research, drives change through advocacy, and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved:, Facebook, Twitter, Instagram, YouTube or 1-800-344-4867.


© 2021 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.